Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Seer, Inc. - Class A Common Stock (NQ:SEER)

2.235 +0.005 (+0.22%)
Streaming Delayed Price Updated: 12:21 PM EDT, Oct 31, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Seer, Inc. - Class A Common Stock

< Previous 1 2 3 Next >
Seer to Participate in Upcoming November Investor Conferences
From Seer, Inc.
Via GlobeNewswire
Seer to Report Third Quarter 2025 Financial Results on November 6, 2025
From Seer, Inc.
Via GlobeNewswire
RetinalGenix Technologies Contracts with Seer Bio to Explore Early Detection of Neurodegenerative, Systemic, and Retinal Diseases
From RetinalGeniX Technologies, Inc.
Via GlobeNewswire
Seer Highlights How Proteomics Complements Genomics to Advance Precision Medicine at American Society of Human Genetics (ASHG) 2025
Scientific presentations reveal how Seer’s Proteograph Product Suite is a critical component of multi-omic translational studies and enables profiling of protein isoform-specific biomarkers 
From Seer, Inc.
Via GlobeNewswire
Seer Appoints Isaac Ro to its Board of Directors
From Seer, Inc.
Via GlobeNewswire
Seer to Participate in the Morgan Stanley 23rd Annual Global Healthcare Conference
From Seer, Inc.
Via GlobeNewswire
Seer Reports Second Quarter 2025 Financial Results and Reiterates Full Year 2025 Outlook
From Seer, Inc.
Via GlobeNewswire
Seer to Participate in the Canaccord Genuity 45th Annual Growth Conference
From Seer, Inc.
Via GlobeNewswire
Seer to Report Second Quarter 2025 Financial Results on August 6, 2025
From Seer, Inc.
Via GlobeNewswire
Seer’s Proteograph Platform Enables Unprecedented 20,000-Sample Proteomics Study with Korea University to Develop AI-Driven Diagnostics for Cancers in Young Adults
From Seer, Inc.
Via GlobeNewswire
Seer Redefining Deep Unbiased Proteomics with Launch of New Proteograph Workflow at ASMS 2025, Enabling Previously Unattainable Scale and Efficiency
From Seer, Inc.
Via GlobeNewswire
Seer Reports First Quarter 2025 Financial Results and Reiterates Full Year 2025 Outlook
Revenue grew 37%, driven by increased product sales and service revenue 
From Seer, Inc.
Via GlobeNewswire
Seer to Report First Quarter 2025 Financial Results on May 13, 2025
From Seer, Inc.
Via GlobeNewswire
Seer Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Full Year 2025 Outlook
Validated technology with exceptional growth of customer publications and enhanced access to the Proteograph Product Suite with growing demand for Seer Technology Access Center (STAC) 
From Seer, Inc.
Via GlobeNewswire
Seer to Participate in the TD Cowen 45th Annual Health Care Conference
From Seer, Inc.
Via GlobeNewswire
Seer to Feature Proteomic Advancements in Cancer and RNA Therapy Research among other Findings at US HUPO 2025
Seminar from Dr. Jinjun Shi from Brigham and Women's Hospital and Harvard Medical School to highlight study of proteomic perturbations resulting from a novel approach to cancer therapy revealed using... 
From Seer, Inc.
Via GlobeNewswire
Seer to Report Fourth Quarter and Full Year 2024 Financial Results on February 27, 2025
From Seer, Inc.
Via GlobeNewswire
Seer to Present at the J.P. Morgan 43rd Annual Healthcare Conference
From Seer, Inc.
Via GlobeNewswire
Seer Ranked Number 57 Fastest-Growing Company in North America on the 2024 Deloitte Technology Fast 500™
Attributes 2,440% revenue growth to increased adoption of its Proteograph™ Product Suite and exciting discoveries made by Seer customers across multiple areas of biology and disease 
From Seer, Inc.
Via GlobeNewswire
Seer to Participate in Upcoming November Investor Conferences
From Seer, Inc.
Via GlobeNewswire
Seer Reports Third Quarter 2024 Financial Results
Growing enthusiasm for Proteograph Product Suite with multiple larger orders from government agencies and continued strong interest in STAC 
From Seer, Inc.
Via GlobeNewswire
Seer Enters into a Co-Marketing and Sales Agreement with Thermo Fisher Scientific
Collaboration enhances unprecedented access to deep, unbiased proteomics at scale, enabling deeper insights into human biology 
From Seer, Inc.
Via GlobeNewswire
Seer Highlights Capability of Deep Proteomics to Enhance Genomic Insights Into Alzheimer’s, Lung Cancer, and More at ASHG 2024
CoLab session with PrognomiQ and Salk Institute plus multiple presentations of new data offer firsthand look at multi-omic breakthroughs powered by Seer’s Proteograph™ Product Suite 
From Seer, Inc.
Via GlobeNewswire
Seer Showcases Scalable Proteomic Advancements Impacting Alzheimer’s, Population Health, and Xenotransplantation at HUPO 2024
Seer’s Proteograph™ Product Suite reveals new insights into Alzheimer’s pathways, drives population-scale plasma analysis, and captures immune dynamics in xenotransplantation—with additional... 
From Seer, Inc.
Via GlobeNewswire
Seer to Report Third Quarter 2024 Financial Results on November 6, 2024
From Seer, Inc.
Via GlobeNewswire
Seer to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
From Seer, Inc.
Via GlobeNewswire
Seer Appoints Nicolas Roelofs to its Board of Directors
From Seer, Inc.
Via GlobeNewswire
Seer to Participate in the Canaccord Genuity 44th Annual Growth Conference
From Seer, Inc.
Via GlobeNewswire
Seer Reports Second Quarter 2024 Financial Results
Launched STAC in Europe and additional customer papers published in leading journals 
From Seer, Inc.
Via GlobeNewswire
Seer to Report Second Quarter 2024 Financial Results on August 8, 2024
From Seer, Inc.
Via GlobeNewswire
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.